2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 569

Is the Oral Microbiome Involved in the Pathogenesis of Sjogren’s Syndrome?
Abstract Number: 570

Signalling Pathways Identified in Salivary Glands from Primary Sjögren’s Syndrome Patients Reveal Enhanced Adipose Tissue Development, As Demonstrated By Microarray Analysis, Real-Time PCR and Immunohistochemistry
Abstract Number: 571

Anti-Modified Protein Antibody Response Pattern in Primary Sjögren’s Syndrome: Clinical and Prognostic Implications
Abstract Number: 572

Biopsy Accuracy in Sjögren’s Syndrome: Analysis of 803 Patients Presenting with Sicca Syndrome Referred to Labial Salivary Gland Biopsy
Abstract Number: 573

Subepithelial Infiltrate of the Vagina in Primary Sjogren’s Syndrome: The Cause of Vaginal Dryness?
Abstract Number: 574

Is Elastography a New Tool to Differentiate Sjögren Syndrome to Sicca Syndrome?: Results of the Elsa (elastography of salivary glands) Study
Abstract Number: 575

Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study
Abstract Number: 576

Immunosignature-Based Diagnosis and Prediction of Therapeutic Response Enables Retrospective Patient Stratification in a Phase IIa Clinical Trial for VAY736 in Primary Sjögren’s Syndrome
Abstract Number: 577

The Value of C-Reactive Protein As a Predictor of Radiographic Spinal Progression Is Strongly Dependent on β-Fibrinogen and Factor XIII a-Subunit Genotypes in Patients with Axial Spondyloarthritis
Abstract Number: 578

Added Value of Biomarkers Compared to Routine Clinical Parameters for the Prediction of Radiographic Spinal Progression in Axial Spondyloarthritis
Abstract Number: 579

Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis
Abstract Number: 580

Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis
Abstract Number: 581

Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Abstract Number: 582

Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis
Abstract Number: 583

Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].